HF Patients With LVADs Being Treated With SGLT2i

Launched by UNIVERSITY OF CHICAGO · Mar 4, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at how a type of medication called sodium-glucose co-transporter 2 inhibitors (SGLT2i) affects patients with heart failure who have a left ventricular assist device (LVAD). Heart failure means the heart isn't pumping blood as well as it should, and an LVAD is a device that helps the heart pump. The goal of the study is to see how well SGLT2i helps improve the health outcomes for these patients.

To participate in this trial, individuals need to be at least 18 years old and have already had an LVAD implanted. They should not have been taking SGLT2i medications before and must have a certain level of kidney function. Unfortunately, those with Type 1 diabetes or very low kidney function cannot join. If eligible, participants will be among those helping researchers understand how this medication can help heart failure patients with LVADs, contributing to better treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. LVAD implantation
• • 2. Have not already been prescribed management with an SGLT2i
• • 3. Estimated glomerular filtration rate (eGFR) ≥ 30 milliliters(ml)/minute(min)/1.73 meter(m)2
• • 4. Age ≥ 18 years-old
• • 5. Able to provide informed consent
• Exclusion Criteria:
• • 1. Diagnosis of Type 1 diabetes mellitus
• • 2. eGFR \< 30 ml/min/1.73 m2
• • 3. Age \< 18 years-old

Trial Officials